The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Liver Cancer HepaSphere Combined With Cryosurgery
Official Title: HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA)Combined With Cryosurgery for Liver Cancer: Clinical Trial
Study ID: NCT02545556
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography(DSA)combined with cryosurgery for liver cancer.
Detailed Description: By enrolling patients with liver cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction angiography(DSA) combined with cryosurgery for liver cancer.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Central laboratory in Fuda cancer hospital, Guangzhou, Guangdong, China
Name: Lizhi Niu, PhD
Affiliation: Fuda Cancer Hospital
Role: STUDY_CHAIR